1
|
Jin G, Jin M, Jin Z, Gao Z, Yin X. Docetaxel-loaded PEG-albumin nanoparticles with improved antitumor efficiency against non-small cell lung cancer. Oncol Rep 2016; 36:871-6. [PMID: 27279008 DOI: 10.3892/or.2016.4863] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2016] [Accepted: 05/30/2016] [Indexed: 11/06/2022] Open
Abstract
The aim of the present study was mainly to assess the advantage of docetaxel-loaded PEG-albumin nanoparticles (PEG-DANPs) against non-small cell lung cancer (NSCLC) compared with the commercial product of docetaxel (Aisu®) and docetaxel-albumin nanoparticles (DANPs). We made systematic assessments on these three drugs against NSCLC both in vitro and in vivo. Based on our experiments, PEG-DANPs showed a dose- and time-dependent efficacy in the in vitro cytotoxicity studies; the tumors growth and the metastases in the livers of NSCLC-bearing nude mice in vivo were reduced dmarkedly by PEG-DANPs, and the PEG-DANP-treated mice had a minimum of weight loss; furthermore, the mice which were treated with PEG-DANPs can survive longer than the other groups. In conclusion, the PEG-DANPs have the lowest side-effects, and the highest antitumor and metastases activity of the three drugs, and it may provide an alternative to patients with NSCLC.
Collapse
Affiliation(s)
- Guangming Jin
- Yanbian University Hospital, Yanji, Jilin 133000, P.R. China
| | - Mingji Jin
- State Key Laboratory of Bioactive Substance and Functions of Natural Medicines, Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P.R. China
| | - Zhehu Jin
- Yanbian University Hospital, Yanji, Jilin 133000, P.R. China
| | - Zhonggao Gao
- State Key Laboratory of Bioactive Substance and Functions of Natural Medicines, Beijing Key Laboratory of Drug Delivery Technology and Novel Formulations, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, P.R. China
| | - Xuezhe Yin
- Yanbian University Hospital, Yanji, Jilin 133000, P.R. China
| |
Collapse
|
2
|
JIN GUANGMING, JIN MINGJI, YIN XUEZHE, JIN ZHEHU, CHEN LIQING, GAO ZHONGGAO. A comparative study on the effect of docetaxel-albumin nanoparticles and docetaxel-loaded PEG-albumin nanoparticles against non-small cell lung cancer. Int J Oncol 2015; 47:1945-53. [DOI: 10.3892/ijo.2015.3174] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2015] [Accepted: 09/09/2015] [Indexed: 11/06/2022] Open
|
3
|
Gridelli C, Balducci L, Ciardiello F, Di Maio M, Felip E, Langer C, Lilenbaum RC, Perrone F, Senan S, de Marinis F. Treatment of Elderly Patients With Non–Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer 2015; 16:325-33. [DOI: 10.1016/j.cllc.2015.02.006] [Citation(s) in RCA: 59] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2015] [Revised: 02/18/2015] [Accepted: 02/26/2015] [Indexed: 12/29/2022]
|
4
|
Grigorescu AC. Chemotherapy for elderly patients with advanced cancer: A pilot study in Institute of Oncology Bucharest. J Transl Int Med 2015; 3:24-28. [PMID: 27847881 PMCID: PMC4936471 DOI: 10.4103/2224-4018.154291] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Objectives First objective was better understanding of the indications of chemotherapy in elderly with advanced cancer, tolerability and toxicity of chemotherapy in this age group. The second objective was to define current practice in chemotherapy for elderly people with advanced cancer for a selected group of patients treated in Institute of Oncology Bucharest (IOB). Materials and Methods The study makes a clinical analysis of medical records of 27 patients from the archive of Institute of Oncology Bucharest treated by the same doctor. Patients were selected according to: age ≥ 65 years, ECOG performance status 0–1, normal blood counts and blood biochemistry, histological confirmation of the diagnosis of cancer, patients should received at least 3 cycles of chemotherapy. We extract characteristics of the patients to see if they were a homogeneous group of patients and to compare them with data from the literature. Overall survival was calculated by the Kaplan Meyer curve. Results 295 patients more then 65 years were treated in our site in 2 years 2011, 2012. 93 patients received chemotherapy and only 27 patients were enrolled in this study following inclusion criteria. Common sites of cancer were lung and breast. The most used cytostatics for lung cancer was gemcitabine and carboplatine and cyclophosphamide, metotrexat and 5 fluorouracil for breast cancer. Toxicity was mild with the prevalence of hematologic toxicity. Overall survival without taking into account the type of cancer was 27.7 month. Conclusions For selected patients, chemotherapy was well tolerated and appears to prolong survival regardless of the location of cancer. The relatively small number of elderly patients who received chemotherapy is probably due to lack of compliance to treatment, the increased number of co-morbidities and evaluation of performance status only by the ECOG index known not to be good enough to establish the indication of chemotherapy.
Collapse
Affiliation(s)
- Alexandru C Grigorescu
- Department of Medical Oncology, Institute of Oncology Bucharest, Sos Fundeni 252, Zip code: 022328, Romania
| |
Collapse
|
5
|
Ripley RT, Rusch VW. Role of induction therapy: surgical resection of non-small cell lung cancer after induction therapy. Thorac Surg Clin 2013; 23:273-85. [PMID: 23931012 DOI: 10.1016/j.thorsurg.2013.04.004] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Patients with Stage III non-small cell lung cancer are best managed by multimodality therapy. Patients with N2 disease can be treated with induction therapy (usually chemotherapy) followed by surgical resection. Patients whose medical comorbidities preclude surgery should be treated with definitive chemoradiotherapy. T3 or T4 tumors involving the superior sulcus or spine are best managed with induction chemoradiotherapy and surgical resection.
Collapse
Affiliation(s)
- R Taylor Ripley
- Thoracic Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | | |
Collapse
|
6
|
Park S, Kim IR, Baek KK, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Sun JM, Ahn JS, Park K, Jo J, Jung SH, Ahn MJ. Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. Ann Oncol 2013; 24:1630-9. [PMID: 23393122 DOI: 10.1093/annonc/mds649] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Given the more comorbidities with a decline in physiologic reserve, it can be challenging to make appropriate treatment decisions in the elderly. PATIENTS AND METHODS Here, we prospectively evaluated and compared the health-related quality of life (HRQOL) of patients aged ≥ 65 with aged <65 who were treated with a postoperative chemotherapy for completely resected stage Ib, II or IIIa non-small-cell lung cancer (NSCLC). Either four cycles of paclitaxel (Taxol)-carboplatin (PC) or vinorelbine-cisplatin (NP) was used. The HRQOL was assessed with EORTC QLQ-C30 and EORTC QLQ-LC13. RESULTS Between October 2008 and October 2011, a total of 139 patients (aged <65, n = 73; ≥ 65, n = 66) were enrolled, and 127 (91.4%) completed the questionnaire. Overall, the quality of life (QOL) in elderly patients did not significantly deteriorate with adjuvant chemotherapy and the time trend of QOL in elderly patients was similar to that of younger patients. Although the elderly suffered from increased treatment-related adverse events involving sore mouth, peripheral neuropathy and alopecia compared with the baseline, the same time trends were also observed in younger group. The mean dose intensities (MDIs) for PC and NP regimen were not significantly different between the two age groups. CONCLUSIONS Postoperative chemotherapy did not substantially reduce HRQOL in elderly NSCLC patients, and HRQOL during and after adjuvant chemotherapy did not significantly differ by age.
Collapse
Affiliation(s)
- S Park
- Division of Hematology-Oncology, Department of Medicine, Research Institute for Future Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Ding ZY, Zhou L, Liu YM, Lu Y. Safety and efficacy of paclitaxel liposome for elderly patients with advanced non-small cell lung cancer: A multi-center prospective study. Thorac Cancer 2013; 4:14-19. [DOI: 10.1111/j.1759-7714.2012.00134.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
8
|
Sun HB, Wang SY, Ou W, Zhang BB, Yang H, Fang Q. The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected locally advanced non-small cell lung cancer. Lung Cancer 2009; 68:403-8. [PMID: 19913325 DOI: 10.1016/j.lungcan.2009.10.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2009] [Revised: 09/29/2009] [Accepted: 10/01/2009] [Indexed: 01/20/2023]
Abstract
BACKGROUND Adjuvant cisplatin-based chemotherapy benefits selected patients with stages II and III non-small cell lung cancer (NSCLC). However, carboplatin being tolerated better than cisplatin, carboplatin-based adjuvant therapy may have better chemotherapy compliance. This study aimed to investigate the feasibility and toxicity of adjuvant carboplatin and docetaxel in patients with completely resected locally advanced NSCLC. METHODS Eighty patients with completely resected locally advanced NSCLC were enrolled in this trial. Adjuvant chemotherapy was initiated between 1 and 4 weeks after surgery, and consisted of four cycles of carboplatin (AUC=5), and docetaxel (Taxotere, 75mg/m(2)) every 3 weeks, after which patients received prophylactic G-CSF supportive therapy. RESULTS Patient demographics were: Median age 55 years (range 34-73): gender ratio was 56.3% male/43.7% female: 72.5% of the patients were at stage IIIA and 27.5% were at stage IIIB. The two most common histologies were adenocarcinoma (62.5%) and squamous cell carcinoma (17.5%). Sixty-six patients (82.5%) received four cycles of therapy over a 12-week period. Fourteen patients (17.5%) did not complete therapy due to: patient refusal (n=12), severe adverse events (n=1) and bone metastases during chemotherapy (n=1). No treatment related deaths were observed and the primary adverse events were hematologic toxicity, alopecia, fatigue and gastointestinal reaction (nausea, vomiting and diarrhea). CONCLUSION Combination therapy with carboplatin and docetaxel with the use of G-CSF supportive therapy has an acceptable toxicity profile such that the majority of patients completed four cycles of therapy in 12 weeks.
Collapse
Affiliation(s)
- Hai-Bo Sun
- Cancer Center of Sun Yat-sen University, Guangzhou, PR China
| | | | | | | | | | | |
Collapse
|
9
|
Browner I, Purtell M. Chemotherapy in the Older Patient with Operable Non–Small Cell Lung Cancer: Neoadjuvant and Adjuvant Regimens. Thorac Surg Clin 2009; 19:377-89. [DOI: 10.1016/j.thorsurg.2009.07.005] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Markovic J, Stojsic J, Zunic S, Ruzdijic S, Tanic N. Genomic instability in patients with non-small cell lung cancer assessed by the arbitrarily primed polymerase chain reaction. Cancer Invest 2008; 26:262-8. [PMID: 18317967 DOI: 10.1080/07357900701708385] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
In the present study, we used DNA profiling to measure genomic instability in 22 patients with non-small cell lung cancer (NSCLC). Genomic instability was correlated with gender, the age of the patients at the time of diagnosis, the NSCLC subtype, histological grade and stage of the tumor, necrosis presence in the tumor and lymph node invasion. Genomic instability was significantly higher in patients older than 50 and those with adenocarcinoma compared to squamous-cell carcinoma. Most importantly, genomic instability significantly decreased as the tumor grade increased. Extensive genomic instability in the early carcinogenesis could be the prerequisite for NSCLC progression.
Collapse
Affiliation(s)
- Jasna Markovic
- Department of Neurobiology, Institute for Biological Research, University of Belgrade, Belgrade, Serbia
| | | | | | | | | |
Collapse
|
11
|
Kim HS, Hyun DS, Kim KC, Lee SC, Jung TH, Park JY, Kim CH, Cha SI, Lee KH, Chung JH, Shin KC, Jeon YJ, Han SB, Choi WI, Kim YJ, Chung CY, Lim GI. The Clinical Characteristics and Prognosis of Elderly Patients with Lung Cancer Diagnosed in Daegu and Gyeongsangbukdo. Tuberc Respir Dis (Seoul) 2008. [DOI: 10.4046/trd.2008.65.1.15] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Affiliation(s)
- Hyun Sook Kim
- Department of Internal Medicine, College of Medicine, Catholic University of Daegu, Korea
| | - Dae Sung Hyun
- Department of Internal Medicine, College of Medicine, Catholic University of Daegu, Korea
| | - Kyung Chan Kim
- Department of Internal Medicine, College of Medicine, Catholic University of Daegu, Korea
| | - Sang Chae Lee
- Department of Internal Medicine, College of Medicine, Catholic University of Daegu, Korea
| | - Tae Hoon Jung
- Department of Internal Medicine, College of Medicine, Kyungpook National University, Korea
| | - Jae Yong Park
- Department of Internal Medicine, College of Medicine, Kyungpook National University, Korea
| | - Chang Ho Kim
- Department of Internal Medicine, College of Medicine, Kyungpook National University, Korea
| | - Seung Ick Cha
- Department of Internal Medicine, College of Medicine, Kyungpook National University, Korea
| | - Kwan Ho Lee
- Department of Internal Medicine, College of Medicine, Yeungnam University, Korea
| | - Jin Hong Chung
- Department of Internal Medicine, College of Medicine, Yeungnam University, Korea
| | - Kyeong Cheol Shin
- Department of Internal Medicine, College of Medicine, Yeungnam University, Korea
| | - Young June Jeon
- Department of Internal Medicine, College of Medicine, Keimyung University, Korea
| | - Seong Beom Han
- Department of Internal Medicine, College of Medicine, Keimyung University, Korea
| | - Won Il Choi
- Department of Internal Medicine, College of Medicine, Keimyung University, Korea
| | - Yeun Jae Kim
- Department of Internal Medicine, Daegu Fatima Hospital, Korea
| | - Chi Young Chung
- Department of Internal Medicine, Daegu Fatima Hospital, Korea
| | - Geon Il Lim
- Department of Internal Medicine, College of Medicine, Soonchunhyang University, Gumi, Korea
| |
Collapse
|